{"generic":"Poliovirus Vaccine, Inactivated","drugs":["Ipol","Poliovirus Vaccine, Inactivated"],"mono":{"0":{"id":"472670-s-0","title":"Generic Names","mono":"Poliovirus Vaccine, Inactivated"},"1":{"id":"472670-s-1","title":"Dosing and Indications","sub":{"0":{"id":"472670-s-1-4","title":"Adult Dosing","mono":"<ul><li>routine primary poliovirus immunization of adults in the United States is not recommended<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> unvaccinated and increased risk for exposure: 0.5 mL IM or SUBQ x 3 doses at  0, 1 to 2 months, and 6 to 12 months<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> unvaccinated and 2 to less than 3 months available before protection is needed: 0.5 mL IM or SUBQ x 3 doses at least 1 month apart<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> unvaccinated and 1 to 2 months available before protection is needed: 0.5 mL IM or SUBQ x 2 doses at least 1 month apart<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> unvaccinated and less than 1 month available before protection is needed: 0.5 mL IM or SUBQ single dose<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> incompletely vaccinated with oral or injectable vaccine and increased risk for exposure: 0.5 mL IM or SUBQ x 1 dose; complete a primary series if time permits<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> completely vaccinated and increased risk of exposure: 0.5 mL IM or SUBQ single dose<\/li><\/ul>"},"1":{"id":"472670-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> unvaccinated: 0.5 mL IM or SUBQ x 4 doses at age 2, 4, 6 to 18 months, and booster at age 4 to 6 years; minimum age to start series is 6 weeks; do not give the first 3 doses more frequently than 4 weeks apart; give the fourth dose at least 6 months after the third dose<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> incompletely vaccinated: 0.5 mL IM or SUBQ x 1 to 3 doses to complete a 4-dose series regardless of age and when both oral and injectable vaccine were administered as part of a series; dose 4 is not required if dose 3 is administered at age 4 years or older and at least 6 months after previous dose<\/li><li><b>Poliomyelitis, acute; Prophylaxis:<\/b> completely vaccinated before age 4 years: 0.5 mL IM or SUBQ x 1 dose as additional dose at age 4 to 6 years and at least 6 months after previous dose<\/li><\/ul>"},"3":{"id":"472670-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Poliomyelitis, acute; Prophylaxis<br\/>"}}},"3":{"id":"472670-s-3","title":"Contraindications\/Warnings","sub":[{"id":"472670-s-3-9","title":"Contraindications","mono":"<ul><li>acute febrile illness; defer vaccination until after recovery (manufacturer); acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction (CDC)<\/li><li>anaphylaxis or anaphylactic shock occurring within 24 hours of administration of one dose of vaccine; no further doses should be given<\/li><li>hypersensitivity to any component of the vaccine, including 2-phenoxyethanol, formaldehyde, streptomycin, neomycin, and polymixin B<\/li><\/ul>"},{"id":"472670-s-3-10","title":"Precautions","mono":"<ul><li>allergic reactions to neomycin, streptomycin, polymixin B, 2-phenoxyethanol and formaldehyde (used in the production of this vaccine) may occur<\/li><li>Guillain-Barre syndrome has been reported<\/li><li>immunodeficient patients or patients under immunosuppressive therapy may not develop a protective immune response against paralytic poliomyelitis after administration<\/li><li>pregnancy; can be administered if there is a risk for exposure to wild-type poliovirus infection<\/li><\/ul>"},{"id":"472670-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"472670-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"5":{"id":"472670-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Swelling<\/li><li><b>Dermatologic:<\/b>Injection site pain<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite, Vomiting<\/li><li><b>Neurologic:<\/b>Fatigue<\/li><li><b>Psychiatric:<\/b>Irritability<\/li><li><b>Other:<\/b>Fever<\/li><\/ul>"},"6":{"id":"472670-s-6","title":"Drug Name Info","sub":{"0":{"id":"472670-s-6-17","title":"US Trade Names","mono":"Ipol<br\/>"},"2":{"id":"472670-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"472670-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"472670-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"472670-s-7","title":"Mechanism Of Action","mono":"Inactivated poliovirus vaccine is a highly purified trivalent vaccine that stimulates production of neutralizing antibodies against poliovirus type 1, 2 and 3 and stimulates antibody responses in most children.<br\/>"},"9":{"id":"472670-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>may be administered IM or subQ; not for IV administration<\/li><li>do not mix with other vaccines in the same syringe<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>infants and small children; preferred injection site is in the mid-lateral aspect of the thigh<\/li><li>older children and adults; preferred injection site is in the tissue of the deltoid area<\/li><li>preferred dosing interval is at least 8 weeks; minimum dosing interval is 4 weeks<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>infants and small children; preferred injection site is in the mid-lateral aspect of the thigh<\/li><li>older children and adults; preferred injection site is in the tissue of the deltoid area<\/li><li>preferred dosing interval is at least 8 weeks; minimum dosing interval is 4 weeks<\/li><\/ul><\/li><\/ul>"},"11":{"id":"472670-s-11","title":"How Supplied","mono":"<b>Ipol<\/b><br\/>Injection Suspension: 80 D Antigen U\/0.5 ML<br\/>"},"13":{"id":"472670-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause swelling, injection site pain, loss of appetite, vomiting, fatigue, irritability, or fever.<\/li><li>Patient should monitor for and report signs\/symptoms of a severe allergic reaction, especially within the first 24 h after receiving vaccine.<\/li><li>If patient has acute febrile illness before a scheduled dose, advise patient to immediately notify healthcare professional, as vaccination may need to be deferred until patient is well.<\/li><li>Instruct patient to call healthcare professional if a treatment is missed, as drug should be given in a fixed series. Emphasize importance of receiving all doses of vaccine in the series.<\/li><\/ul>"}}}